ID MK01_MOUSE Reviewed; 358 AA. AC P63085; P27703; Q3V1U6; DT 13-SEP-2004, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 3. DT 27-MAR-2024, entry version 206. DE RecName: Full=Mitogen-activated protein kinase 1 {ECO:0000305}; DE Short=MAP kinase 1; DE Short=MAPK 1; DE EC=2.7.11.24; DE AltName: Full=ERT1; DE AltName: Full=Extracellular signal-regulated kinase 2; DE Short=ERK-2; DE AltName: Full=MAP kinase isoform p42; DE Short=p42-MAPK; DE AltName: Full=Mitogen-activated protein kinase 2; DE Short=MAP kinase 2; DE Short=MAPK 2; GN Name=Mapk1 {ECO:0000312|MGI:MGI:1346858}; Synonyms=Erk2, Mapk, Prkm1; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Mus; Mus. OX NCBI_TaxID=10090; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC STRAIN=SWR/J; TISSUE=Fibroblast; RX PubMed=1649458; DOI=10.1093/nar/19.13.3743; RA Her J.-H., Wu J.-S., Rall T.B., Sturgill T.W., Weber M.J.; RT "Sequence of pp42/MAP kinase, a serine/threonine kinase regulated by RT tyrosine phosphorylation."; RL Nucleic Acids Res. 19:3743-3743(1991). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC STRAIN=C57BL/6J, and NOD; RC TISSUE=Brain, Head, Thymus, and Urinary bladder; RX PubMed=16141072; DOI=10.1126/science.1112014; RA Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N., RA Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K., RA Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J., RA Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R., RA Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T., RA Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A., RA Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., RA Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M., RA Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S., RA Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E., RA Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D., RA Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M., RA Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H., RA Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V., RA Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S., RA Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H., RA Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N., RA Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F., RA Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., RA Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., RA Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C., RA Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y., RA Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S., RA Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K., RA Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R., RA van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H., RA Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M., RA Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C., RA Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S., RA Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K., RA Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M., RA Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C., RA Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A., RA Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.; RT "The transcriptional landscape of the mammalian genome."; RL Science 309:1559-1563(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP PROTEIN SEQUENCE OF 54-65; 76-89; 137-162; 171-189; 193-201 AND 260-268, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RC STRAIN=C57BL/6J, and OF1; TISSUE=Brain, and Hippocampus; RA Lubec G., Klug S., Kang S.U., Sunyer B., Chen W.-Q.; RL Submitted (JAN-2009) to UniProtKB. RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 152-190. RC STRAIN=CBA/J; TISSUE=Bone marrow; RX PubMed=8444355; DOI=10.1016/0378-1119(93)90411-u; RA Ershler M.A., Nagorskaya T.V., Visser J.W.M., Belyavsky A.V.; RT "Novel CDC2-related protein kinases produced in murine hematopoietic stem RT cells."; RL Gene 124:305-306(1993). RN [6] RP PHOSPHORYLATION AT THR-183 AND TYR-185, AND PARTIAL PROTEIN SEQUENCE. RX PubMed=1849075; DOI=10.1002/j.1460-2075.1991.tb08021.x; RA Payne D.M., Rossomando A.J., Martino P., Erickson A.K., Her J.-H., RA Shabanowitz J., Hunt D.F., Weber M.J., Sturgill T.W.; RT "Identification of the regulatory phosphorylation sites in pp42/mitogen- RT activated protein kinase (MAP kinase)."; RL EMBO J. 10:885-892(1991). RN [7] RP PHOSPHORYLATION AT THR-183 AND TYR-185, DEPHOSPHORYLATION BY DUSP1, AND RP ACTIVITY REGULATION. RX PubMed=8221888; DOI=10.1016/0092-8674(93)90383-2; RA Sun H., Charles C.H., Lau L.F., Tonks N.K.; RT "MKP-1 (3CH134), an immediate early gene product, is a dual specificity RT phosphatase that dephosphorylates MAP kinase in vivo."; RL Cell 75:487-493(1993). RN [8] RP PHOSPHORYLATION IN RESPONSE TO FLT3 SIGNALING. RX PubMed=10080542; DOI=10.1002/jlb.65.3.372; RA Zhang S., Mantel C., Broxmeyer H.E.; RT "Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and RT their association with Grb2 and Shc in Baf3/Flt3 cells."; RL J. Leukoc. Biol. 65:372-380(1999). RN [9] RP PHOSPHORYLATION IN RESPONSE TO FLT3 SIGNALING. RX PubMed=11090077; RA Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C., RA Gruning W., Kratz-Albers K., Serve S., Steur C., Buchner T., Kienast J., RA Kanakura Y., Berdel W.E., Serve H.; RT "Flt3 mutations from patients with acute myeloid leukemia induce RT transformation of 32D cells mediated by the Ras and STAT5 pathways."; RL Blood 96:3907-3914(2000). RN [10] RP FUNCTION IN PHOSPHORYLATION OF PXN. RX PubMed=10753946; DOI=10.1074/jbc.275.15.11333; RA Ku H., Meier K.E.; RT "Phosphorylation of paxillin via the ERK mitogen-activated protein kinase RT cascade in EL4 thymoma cells."; RL J. Biol. Chem. 275:11333-11340(2000). RN [11] RP INTERACTION WITH PEA15, SUBCELLULAR LOCATION, AND FUNCTION OF THE MAPK ERK RP CASCADE. RX PubMed=11702783; DOI=10.1016/s1534-5807(01)00035-1; RA Formstecher E., Ramos J.W., Fauquet M., Calderwood D.A., Hsieh J.C., RA Canton B., Nguyen X.T., Barnier J.V., Camonis J., Ginsberg M.H., RA Chneiweiss H.; RT "PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase."; RL Dev. Cell 1:239-250(2001). RN [12] RP FUNCTION IN PHOSPHORYLATION OF FOS, AND SUBCELLULAR LOCATION. RX PubMed=12134156; DOI=10.1038/ncb822; RA Murphy L.O., Smith S., Chen R.H., Fingar D.C., Blenis J.; RT "Molecular interpretation of ERK signal duration by immediate early gene RT products."; RL Nat. Cell Biol. 4:556-564(2002). RN [13] RP INTERACTION WITH MORG1. RX PubMed=15118098; DOI=10.1073/pnas.0305894101; RA Vomastek T., Schaeffer H.-J., Tarcsafalvi A., Smolkin M.E., RA Bissonette E.A., Weber M.J.; RT "Modular construction of a signaling scaffold: MORG1 interacts with RT components of the ERK cascade and links ERK signaling to specific RT agonists."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6981-6986(2004). RN [14] RP PHOSPHORYLATION OF SPZ1. RX PubMed=15899793; DOI=10.1158/0008-5472.can-04-3658; RA Hsu S.-H., Hsieh-Li H.-M., Huang H.-Y., Huang P.-H., Li H.; RT "bHLH-zip transcription factor Spz1 mediates mitogen-activated protein RT kinase cell proliferation, transformation, and tumorigenesis."; RL Cancer Res. 65:4041-4050(2005). RN [15] RP INTERACTION WITH GIT1, AND SUBCELLULAR LOCATION. RX PubMed=15923189; DOI=10.1074/jbc.m502271200; RA Yin G., Zheng Q., Yan C., Berk B.C.; RT "GIT1 is a scaffold for ERK1/2 activation in focal adhesions."; RL J. Biol. Chem. 280:27705-27712(2005). RN [16] RP INTERACTION WITH MKNK2. RX PubMed=16162500; DOI=10.1074/jbc.m508356200; RA Parra J.L., Buxade M., Proud C.G.; RT "Features of the catalytic domains and C termini of the MAPK signal- RT integrating kinases Mnk1 and Mnk2 determine their differing activities and RT regulatory properties."; RL J. Biol. Chem. 280:37623-37633(2005). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-183 AND TYR-185, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Mast cell; RX PubMed=17947660; DOI=10.4049/jimmunol.179.9.5864; RA Cao L., Yu K., Banh C., Nguyen V., Ritz A., Raphael B.J., Kawakami Y., RA Kawakami T., Salomon A.R.; RT "Quantitative time-resolved phosphoproteomic analysis of mast cell RT signaling."; RL J. Immunol. 179:5864-5876(2007). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-183 AND TYR-185, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=17242355; DOI=10.1073/pnas.0609836104; RA Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.; RT "Large-scale phosphorylation analysis of mouse liver."; RL Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-183 AND TYR-185, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Brain; RX PubMed=18034455; DOI=10.1021/pr0701254; RA Ballif B.A., Carey G.R., Sunyaev S.R., Gygi S.P.; RT "Large-scale identification and evolution indexing of tyrosine RT phosphorylation sites from murine brain."; RL J. Proteome Res. 7:311-318(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-183 AND TYR-185, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic fibroblast; RX PubMed=19131326; DOI=10.1074/mcp.m800451-mcp200; RA Sweet S.M., Bailey C.M., Cunningham D.L., Heath J.K., Cooper H.J.; RT "Large scale localization of protein phosphorylation by use of electron RT capture dissociation mass spectrometry."; RL Mol. Cell. Proteomics 8:904-912(2009). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-183 AND TYR-185, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung, RC Pancreas, Spleen, and Testis; RX PubMed=21183079; DOI=10.1016/j.cell.2010.12.001; RA Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R., RA Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.; RT "A tissue-specific atlas of mouse protein phosphorylation and expression."; RL Cell 143:1174-1189(2010). RN [22] RP PHOSPHORYLATION IN RESPONSE TO FLT3 SIGNALING. RX PubMed=21262971; DOI=10.1074/jbc.m110.205021; RA Arora D., Stopp S., Bohmer S.A., Schons J., Godfrey R., Masson K., RA Razumovskaya E., Ronnstrand L., Tanzer S., Bauer R., Bohmer F.D., RA Muller J.P.; RT "Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 RT signaling."; RL J. Biol. Chem. 286:10918-10929(2011). RN [23] RP REVIEW ON FUNCTION. RX PubMed=16393692; DOI=10.1080/02699050500284218; RA Yoon S., Seger R.; RT "The extracellular signal-regulated kinase: multiple substrates regulate RT diverse cellular functions."; RL Growth Factors 24:21-44(2006). RN [24] RP REVIEW ON FUNCTION, AND REVIEW ON SUBCELLULAR LOCATION. RX PubMed=19565474; DOI=10.1002/biof.52; RA Yao Z., Seger R.; RT "The ERK signaling cascade--views from different subcellular RT compartments."; RL BioFactors 35:407-416(2009). RN [25] RP REVIEW ON ACTIVITY REGULATION, AND REVIEW ON FUNCTION. RX PubMed=21779493; DOI=10.1177/1947601911407328; RA Wortzel I., Seger R.; RT "The ERK cascade: distinct functions within various subcellular RT organelles."; RL Genes Cancer 2:195-209(2011). RN [26] RP ISGYLATION. RX PubMed=22022510; DOI=10.1371/journal.pone.0026068; RA Maragno A.L., Pironin M., Alcalde H., Cong X., Knobeloch K.P., Tangy F., RA Zhang D.E., Ghysdael J., Quang C.T.; RT "ISG15 modulates development of the erythroid lineage."; RL PLoS ONE 6:E26068-E26068(2011). RN [27] RP FUNCTION IN PHOSPHORYLATION OF FXR1. RX PubMed=26240334; DOI=10.1073/pnas.1506491112; RA Del'Guidice T., Latapy C., Rampino A., Khlghatyan J., Lemasson M., RA Gelao B., Quarto T., Rizzo G., Barbeau A., Lamarre C., Bertolino A., RA Blasi G., Beaulieu J.M.; RT "FXR1P is a GSK3beta substrate regulating mood and emotion processing."; RL Proc. Natl. Acad. Sci. U.S.A. 112:E4610-E4619(2015). RN [28] RP INTERACTION WITH DUSP7. RX PubMed=27783954; DOI=10.1016/j.celrep.2016.10.007; RA Tischer T., Schuh M.; RT "The phosphatase Dusp7 drives meiotic resumption and chromosome alignment RT in mouse oocytes."; RL Cell Rep. 17:1426-1437(2016). CC -!- FUNCTION: Serine/threonine kinase which acts as an essential component CC of the MAP kinase signal transduction pathway. MAPK1/ERK2 and CC MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK CC cascade. They participate also in a signaling cascade initiated by CC activated KIT and KITLG/SCF. Depending on the cellular context, the CC MAPK/ERK cascade mediates diverse biological functions such as cell CC growth, adhesion, survival and differentiation through the regulation CC of transcription, translation, cytoskeletal rearrangements. The CC MAPK/ERK cascade also plays a role in initiation and regulation of CC meiosis, mitosis, and postmitotic functions in differentiated cells by CC phosphorylating a number of transcription factors. About 160 substrates CC have already been discovered for ERKs. Many of these substrates are CC localized in the nucleus, and seem to participate in the regulation of CC transcription upon stimulation. However, other substrates are found in CC the cytosol as well as in other cellular organelles, and those are CC responsible for processes such as translation, mitosis and apoptosis. CC Moreover, the MAPK/ERK cascade is also involved in the regulation of CC the endosomal dynamics, including lysosome processing and endosome CC cycling through the perinuclear recycling compartment (PNRC); as well CC as in the fragmentation of the Golgi apparatus during mitosis. The CC substrates include transcription factors (such as ATF2, BCL6, ELK1, CC ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, CC GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such CC as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of CC translation (such as EIF4EBP1 and FXR1) and a variety of other CC signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein CC kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, CC RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, CC MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or CC DUSP16) are other substrates which enable the propagation the MAPK/ERK CC signal to additional cytosolic and nuclear targets, thereby extending CC the specificity of the cascade. Mediates phosphorylation of TPR in CC response to EGF stimulation. May play a role in the spindle assembly CC checkpoint. Phosphorylates PML and promotes its interaction with PIN1, CC leading to PML degradation. Phosphorylates CDK2AP2 (By similarity). CC {ECO:0000250|UniProtKB:P28482, ECO:0000250|UniProtKB:P63086, CC ECO:0000269|PubMed:10753946, ECO:0000269|PubMed:11702783, CC ECO:0000269|PubMed:12134156, ECO:0000269|PubMed:26240334, CC ECO:0000303|PubMed:16393692, ECO:0000303|PubMed:19565474, CC ECO:0000303|PubMed:21779493}. CC -!- FUNCTION: Acts as a transcriptional repressor. Binds to a [GC]AAA[GC] CC consensus sequence. Repress the expression of interferon gamma-induced CC genes. Seems to bind to the promoter of CCL5, DMP1, IFIH1, IFITM1, CC IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and STAT1. Transcriptional activity CC is independent of kinase activity. {ECO:0000250|UniProtKB:P28482}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl- CC [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24; CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L- CC threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, CC Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.24; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2 on CC Thr-183 and Tyr-185 in response to external stimuli like insulin or CC NGF. Both phosphorylations are required for activity. This CC phosphorylation causes dramatic conformational changes, which enable CC full activation and interaction of MAPK1/ERK2 with its substrates. CC Phosphorylation on Ser-27 by SGK1 results in its activation by CC enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. CC Dephosphorylated and inactivated by DUSP1, DUSP3, DUSP6 and DUSP9. CC Inactivated by pyrimidylpyrrole inhibitors. CC {ECO:0000269|PubMed:8221888}. CC -!- SUBUNIT: Binds both upstream activators and downstream substrates in CC multimolecular complexes. This interaction inhibits its tyrosine-kinase CC activity. Interacts with ADAM15, ARHGEF2, ARRB2, DAPK1 (via death CC domain), HSF4, IER3, IPO7, NISCH, SGK1, and isoform 1 of NEK2. CC Interacts (via phosphorylated form) with TPR (via C-terminal region and CC phosphorylated form); the interaction requires dimerization of CC MAPK1/ERK2 and increases following EGF stimulation (By similarity). CC Interacts with MAP2K1 (By similarity). Interacts with DUSP6 (By CC similarity). Interacts (phosphorylated form) with CAV2 ('Tyr-19'- CC phosphorylated form); the interaction, promoted by insulin, leads to CC nuclear location and MAPK1 activation. Interacts with DCC (By CC similarity). Interacts with MORG1 (PubMed:15118098). Interacts with CC PEA15 (PubMed:16162500). Interacts with MKNK2. MKNK2 isoform 1 binding CC prevents from dephosphorylation and inactivation (PubMed:11702783). The CC phosphorylated form interacts with PML. Interacts with STYX. Interacts CC with CDK2AP2. Interacts with CAVIN4 (By similarity). Interacts with CC DUSP7; the interaction enhances DUSP7 phosphatase activity CC (PubMed:27783954). Interacts with GIT1; this interaction is necessary CC for MAPK1 localization to focal adhesions (PubMed:15923189). Interacts CC with ZNF263 (By similarity). {ECO:0000250|UniProtKB:P28482, CC ECO:0000250|UniProtKB:P63086, ECO:0000269|PubMed:11702783, CC ECO:0000269|PubMed:15118098, ECO:0000269|PubMed:15923189, CC ECO:0000269|PubMed:16162500, ECO:0000269|PubMed:27783954}. CC -!- INTERACTION: CC P63085; Q62108: Dlg4; NbExp=4; IntAct=EBI-397697, EBI-300895; CC P63085; Q9DBB1: Dusp6; NbExp=2; IntAct=EBI-397697, EBI-7812384; CC P63085; Q03172: Hivep1; NbExp=4; IntAct=EBI-397697, EBI-646850; CC P63085; P63085: Mapk1; NbExp=5; IntAct=EBI-397697, EBI-397697; CC P63085; Q8CDB0: Mknk2; NbExp=23; IntAct=EBI-397697, EBI-646209; CC P63085; Q8R332-1: Nup58; NbExp=3; IntAct=EBI-397697, EBI-646962; CC P63085; Q62132: Ptprr; NbExp=5; IntAct=EBI-397697, EBI-6954051; CC P63085; Q9Z2B9: Rps6ka4; NbExp=3; IntAct=EBI-397697, EBI-412887; CC P63085; P49841: GSK3B; Xeno; NbExp=2; IntAct=EBI-397697, EBI-373586; CC P63085; O95863: SNAI1; Xeno; NbExp=3; IntAct=EBI-397697, EBI-1045459; CC P63085; A0A0F6AZL3: sseI; Xeno; NbExp=3; IntAct=EBI-397697, EBI-16463657; CC P63085; G3G926: US2; Xeno; NbExp=8; IntAct=EBI-397697, EBI-11692733; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, spindle {ECO:0000250}. CC Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, CC centrosome {ECO:0000250}. Cytoplasm. Membrane, caveola CC {ECO:0000250|UniProtKB:P63086}. Cell junction, focal adhesion CC {ECO:0000269|PubMed:15923189}. Note=Associated with the spindle during CC prometaphase and metaphase (By similarity). PEA15-binding and CC phosphorylated DAPK1 promote its cytoplasmic retention. Phosphorylation CC at Ser-244 and Ser-246 as well as autophosphorylation at Thr-188 CC promote nuclear localization (By similarity). Localization to focal CC adhesions is stimulated by EGF (PubMed:15923189). {ECO:0000250, CC ECO:0000269|PubMed:15923189}. CC -!- TISSUE SPECIFICITY: Widely expressed. CC -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues CC whose phosphorylation activates the MAP kinases. CC -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185, which activates the CC enzyme. Ligand-activated ALK induces tyrosine phosphorylation (By CC similarity). Dephosphorylated by PTPRJ at Tyr-185 (By similarity). CC Phosphorylated upon FLT3 and KIT signaling (By similarity). CC Dephosphorylated by DUSP1 and DUSP2 at Thr-183 and Tyr-185 (By CC similarity) (PubMed:8221888). {ECO:0000250, CC ECO:0000250|UniProtKB:P28482, ECO:0000269|PubMed:8221888}. CC -!- PTM: ISGylated. {ECO:0000269|PubMed:22022510}. CC -!- PTM: Ubiquitinated by TRIM15 via 'Lys-63'-linked ubiquitination; CC leading to activation. Deubiquitinated by CYLD. CC {ECO:0000250|UniProtKB:P27361}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. MAP kinase subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X58712; CAA41548.1; -; mRNA. DR EMBL; AK035386; BAC29053.1; -; mRNA. DR EMBL; AK048127; BAC33251.1; -; mRNA. DR EMBL; AK087925; BAC40044.1; -; mRNA. DR EMBL; AK132241; BAE21053.1; -; mRNA. DR EMBL; BC058258; AAH58258.1; -; mRNA. DR EMBL; D10939; BAA01733.1; -; mRNA. DR CCDS; CCDS27992.1; -. DR PIR; S16444; S16444. DR RefSeq; NP_001033752.1; NM_001038663.1. DR RefSeq; NP_036079.1; NM_011949.3. DR RefSeq; XP_006522210.1; XM_006522147.3. DR AlphaFoldDB; P63085; -. DR BMRB; P63085; -. DR SMR; P63085; -. DR BioGRID; 204966; 87. DR CORUM; P63085; -. DR DIP; DIP-661N; -. DR ELM; P63085; -. DR IntAct; P63085; 41. DR MINT; P63085; -. DR STRING; 10090.ENSMUSP00000065983; -. DR BindingDB; P63085; -. DR ChEMBL; CHEMBL2207; -. DR MoonDB; P63085; Predicted. DR iPTMnet; P63085; -. DR PhosphoSitePlus; P63085; -. DR SwissPalm; P63085; -. DR EPD; P63085; -. DR jPOST; P63085; -. DR MaxQB; P63085; -. DR PaxDb; 10090-ENSMUSP00000065983; -. DR PeptideAtlas; P63085; -. DR ProteomicsDB; 295630; -. DR Pumba; P63085; -. DR Antibodypedia; 3785; 2169 antibodies from 55 providers. DR DNASU; 26413; -. DR Ensembl; ENSMUST00000069107.14; ENSMUSP00000065983.8; ENSMUSG00000063358.18. DR Ensembl; ENSMUST00000115731.10; ENSMUSP00000111396.2; ENSMUSG00000063358.18. DR Ensembl; ENSMUST00000232611.2; ENSMUSP00000156154.2; ENSMUSG00000063358.18. DR GeneID; 26413; -. DR KEGG; mmu:26413; -. DR UCSC; uc007yjq.1; mouse. DR AGR; MGI:1346858; -. DR CTD; 5594; -. DR MGI; MGI:1346858; Mapk1. DR VEuPathDB; HostDB:ENSMUSG00000063358; -. DR eggNOG; KOG0660; Eukaryota. DR GeneTree; ENSGT00940000156771; -. DR HOGENOM; CLU_000288_181_1_1; -. DR InParanoid; P63085; -. DR OMA; SFFDFDY; -. DR OrthoDB; 158564at2759; -. DR PhylomeDB; P63085; -. DR TreeFam; TF105097; -. DR BRENDA; 2.7.11.24; 3474. DR Reactome; R-MMU-111995; phospho-PLA2 pathway. DR Reactome; R-MMU-112409; RAF-independent MAPK1/3 activation. DR Reactome; R-MMU-112411; MAPK1 (ERK2) activation. DR Reactome; R-MMU-1181150; Signaling by NODAL. DR Reactome; R-MMU-1295596; Spry regulation of FGF signaling. DR Reactome; R-MMU-1502540; Signaling by Activin. DR Reactome; R-MMU-162658; Golgi Cisternae Pericentriolar Stack Reorganization. DR Reactome; R-MMU-170968; Frs2-mediated activation. DR Reactome; R-MMU-198753; ERK/MAPK targets. DR Reactome; R-MMU-202670; ERKs are inactivated. DR Reactome; R-MMU-2029482; Regulation of actin dynamics for phagocytic cup formation. DR Reactome; R-MMU-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity. DR Reactome; R-MMU-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-MMU-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-MMU-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-MMU-2559585; Oncogene Induced Senescence. DR Reactome; R-MMU-2871796; FCERI mediated MAPK activation. DR Reactome; R-MMU-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-MMU-375165; NCAM signaling for neurite out-growth. DR Reactome; R-MMU-437239; Recycling pathway of L1. DR Reactome; R-MMU-445144; Signal transduction by L1. DR Reactome; R-MMU-450341; Activation of the AP-1 family of transcription factors. DR Reactome; R-MMU-456926; Thrombin signalling through proteinase activated receptors (PARs). DR Reactome; R-MMU-5654726; Negative regulation of FGFR1 signaling. DR Reactome; R-MMU-5654727; Negative regulation of FGFR2 signaling. DR Reactome; R-MMU-5654732; Negative regulation of FGFR3 signaling. DR Reactome; R-MMU-5654733; Negative regulation of FGFR4 signaling. DR Reactome; R-MMU-5663213; RHO GTPases Activate WASPs and WAVEs. DR Reactome; R-MMU-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-MMU-5673001; RAF/MAP kinase cascade. DR Reactome; R-MMU-5674135; MAP2K and MAPK activation. DR Reactome; R-MMU-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-MMU-5675221; Negative regulation of MAPK pathway. DR Reactome; R-MMU-6798695; Neutrophil degranulation. DR Reactome; R-MMU-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-MMU-74749; Signal attenuation. DR Reactome; R-MMU-877300; Interferon gamma signaling. DR Reactome; R-MMU-881907; Gastrin-CREB signalling pathway via PKC and MAPK. DR Reactome; R-MMU-8939211; ESR-mediated signaling. DR Reactome; R-MMU-9627069; Regulation of the apoptosome activity. DR Reactome; R-MMU-9634635; Estrogen-stimulated signaling through PRKCZ. DR Reactome; R-MMU-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-MMU-9732724; IFNG signaling activates MAPKs. DR Reactome; R-MMU-982772; Growth hormone receptor signaling. DR BioGRID-ORCS; 26413; 10 hits in 81 CRISPR screens. DR ChiTaRS; Mapk1; mouse. DR PRO; PR:P63085; -. DR Proteomes; UP000000589; Chromosome 16. DR RNAct; P63085; Protein. DR Bgee; ENSMUSG00000063358; Expressed in dentate gyrus of hippocampal formation granule cell and 278 other cell types or tissues. DR ExpressionAtlas; P63085; baseline and differential. DR GO; GO:0030424; C:axon; ISO:MGI. DR GO; GO:0005901; C:caveola; ISS:UniProtKB. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:AgBase. DR GO; GO:0005856; C:cytoskeleton; TAS:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:BHF-UCL. DR GO; GO:0032839; C:dendrite cytoplasm; ISO:MGI. DR GO; GO:0005769; C:early endosome; TAS:UniProtKB. DR GO; GO:0005925; C:focal adhesion; TAS:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; TAS:UniProtKB. DR GO; GO:0005770; C:late endosome; TAS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:MGI. DR GO; GO:0072686; C:mitotic spindle; ISS:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; ISO:MGI. DR GO; GO:0005634; C:nucleus; IDA:AgBase. DR GO; GO:0043204; C:perikaryon; ISO:MGI. DR GO; GO:0005886; C:plasma membrane; ISS:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; ISO:MGI. DR GO; GO:0032991; C:protein-containing complex; ISO:MGI. DR GO; GO:0031143; C:pseudopodium; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; ISO:MGI. DR GO; GO:0003690; F:double-stranded DNA binding; ISO:MGI. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:MGI. DR GO; GO:0004707; F:MAP kinase activity; IDA:MGI. DR GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; ISO:MGI. DR GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB. DR GO; GO:0001784; F:phosphotyrosine residue binding; IMP:MGI. DR GO; GO:0004672; F:protein kinase activity; IDA:MGI. DR GO; GO:0019901; F:protein kinase binding; ISO:MGI. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IDA:UniProtKB. DR GO; GO:0030521; P:androgen receptor signaling pathway; ISO:MGI. DR GO; GO:0009887; P:animal organ morphogenesis; IDA:MGI. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0050853; P:B cell receptor signaling pathway; IDA:MGI. DR GO; GO:0060020; P:Bergmann glial cell differentiation; IGI:MGI. DR GO; GO:0061308; P:cardiac neural crest cell development involved in heart development; IGI:MGI. DR GO; GO:0072584; P:caveolin-mediated endocytosis; TAS:UniProtKB. DR GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IBA:GO_Central. DR GO; GO:0034198; P:cellular response to amino acid starvation; ISO:MGI. DR GO; GO:0071276; P:cellular response to cadmium ion; ISO:MGI. DR GO; GO:0071310; P:cellular response to organic substance; ISO:MGI. DR GO; GO:0034614; P:cellular response to reactive oxygen species; ISO:MGI. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IGI:MGI. DR GO; GO:0019858; P:cytosine metabolic process; IDA:MGI. DR GO; GO:0046697; P:decidualization; ISO:MGI. DR GO; GO:0015966; P:diadenosine tetraphosphate biosynthetic process; ISO:MGI. DR GO; GO:0006974; P:DNA damage response; IDA:MGI. DR GO; GO:0006351; P:DNA-templated transcription; NAS:UniProtKB. DR GO; GO:0038127; P:ERBB signaling pathway; ISO:MGI. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IDA:MGI. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IGI:MGI. DR GO; GO:0060324; P:face development; IMP:MGI. DR GO; GO:0007507; P:heart development; IMP:MGI. DR GO; GO:0008286; P:insulin receptor signaling pathway; IDA:MGI. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IDA:MGI. DR GO; GO:0035556; P:intracellular signal transduction; ISO:MGI. DR GO; GO:0060716; P:labyrinthine layer blood vessel development; IMP:MGI. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IDA:MGI. DR GO; GO:0060291; P:long-term synaptic potentiation; IGI:MGI. DR GO; GO:0060425; P:lung morphogenesis; IGI:MGI. DR GO; GO:0033598; P:mammary gland epithelial cell proliferation; IDA:MGI. DR GO; GO:0000165; P:MAPK cascade; IDA:MGI. DR GO; GO:0042552; P:myelination; IMP:MGI. DR GO; GO:0045596; P:negative regulation of cell differentiation; IGI:MGI. DR GO; GO:0014032; P:neural crest cell development; IGI:MGI. DR GO; GO:0042473; P:outer ear morphogenesis; IGI:MGI. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISO:MGI. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISO:MGI. DR GO; GO:0010759; P:positive regulation of macrophage chemotaxis; ISO:MGI. DR GO; GO:0120041; P:positive regulation of macrophage proliferation; ISO:MGI. DR GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; ISO:MGI. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; ISO:MGI. DR GO; GO:1904355; P:positive regulation of telomere capping; ISO:MGI. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISO:MGI. DR GO; GO:0045727; P:positive regulation of translation; ISO:MGI. DR GO; GO:0050847; P:progesterone receptor signaling pathway; ISO:MGI. DR GO; GO:0030641; P:regulation of cellular pH; IMP:MGI. DR GO; GO:0051493; P:regulation of cytoskeleton organization; TAS:UniProtKB. DR GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; NAS:UniProtKB. DR GO; GO:2000641; P:regulation of early endosome to late endosome transport; TAS:UniProtKB. DR GO; GO:0090170; P:regulation of Golgi inheritance; TAS:UniProtKB. DR GO; GO:0030278; P:regulation of ossification; IGI:MGI. DR GO; GO:0031647; P:regulation of protein stability; ISS:UniProtKB. DR GO; GO:0032872; P:regulation of stress-activated MAPK cascade; TAS:UniProtKB. DR GO; GO:0070849; P:response to epidermal growth factor; ISS:UniProtKB. DR GO; GO:0043627; P:response to estrogen; ISO:MGI. DR GO; GO:0043330; P:response to exogenous dsRNA; IDA:MGI. DR GO; GO:0032496; P:response to lipopolysaccharide; IDA:MGI. DR GO; GO:0035094; P:response to nicotine; IGI:ARUK-UCL. DR GO; GO:0009636; P:response to toxic substance; ISO:MGI. DR GO; GO:0014044; P:Schwann cell development; IMP:MGI. DR GO; GO:0019233; P:sensory perception of pain; ISO:MGI. DR GO; GO:0043401; P:steroid hormone mediated signaling pathway; ISO:MGI. DR GO; GO:0051403; P:stress-activated MAPK cascade; ISO:MGI. DR GO; GO:0050852; P:T cell receptor signaling pathway; IDA:MGI. DR GO; GO:0048538; P:thymus development; IGI:MGI. DR GO; GO:0030878; P:thyroid gland development; IGI:MGI. DR GO; GO:0060440; P:trachea formation; IGI:MGI. DR CDD; cd07849; STKc_ERK1_2_like; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR003527; MAP_kinase_CS. DR InterPro; IPR008349; MAPK_ERK1/2. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24055; MITOGEN-ACTIVATED PROTEIN KINASE; 1. DR PANTHER; PTHR24055:SF599; MITOGEN-ACTIVATED PROTEIN KINASE 1; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR01770; ERK1ERK2MAPK. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS01351; MAPK; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR Genevisible; P63085; MM. PE 1: Evidence at protein level; KW Acetylation; Apoptosis; ATP-binding; Cell cycle; Cell junction; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Kinase; Membrane; KW Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P28482" FT CHAIN 2..358 FT /note="Mitogen-activated protein kinase 1" FT /id="PRO_0000186248" FT DOMAIN 23..311 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOTIF 183..185 FT /note="TXY" FT ACT_SITE 147 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 29..37 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 52 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000250|UniProtKB:P28482" FT MOD_RES 27 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000250|UniProtKB:P28482" FT MOD_RES 183 FT /note="Phosphothreonine; by MAP2K1 and MAP2K2" FT /evidence="ECO:0000269|PubMed:1849075, FT ECO:0007744|PubMed:17242355, ECO:0007744|PubMed:17947660, FT ECO:0007744|PubMed:18034455, ECO:0007744|PubMed:19131326, FT ECO:0007744|PubMed:21183079" FT MOD_RES 185 FT /note="Phosphotyrosine; by MAP2K1 and MAP2K2" FT /evidence="ECO:0000269|PubMed:1849075, FT ECO:0007744|PubMed:17242355, ECO:0007744|PubMed:17947660, FT ECO:0007744|PubMed:18034455, ECO:0007744|PubMed:19131326, FT ECO:0007744|PubMed:21183079" FT MOD_RES 188 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P28482" FT MOD_RES 244 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28482" FT MOD_RES 246 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28482" FT MOD_RES 282 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28482" SQ SEQUENCE 358 AA; 41276 MW; 3BBCF22471EDBA0B CRC64; MAAAAAAGPE MVRGQVFDVG PRYTNLSYIG EGAYGMVCSA YDNLNKVRVA IKKISPFEHQ TYCQRTLREI KILLRFRHEN IIGINDIIRA PTIEQMKDVY IVQDLMETDL YKLLKTQHLS NDHICYFLYQ ILRGLKYIHS ANVLHRDLKP SNLLLNTTCD LKICDFGLAR VADPDHDHTG FLTEYVATRW YRAPEIMLNS KGYTKSIDIW SVGCILAEML SNRPIFPGKH YLDQLNHILG ILGSPSQEDL NCIINLKARN YLLSLPHKNK VPWNRLFPNA DSKALDLLDK MLTFNPHKRI EVEQALAHPY LEQYYDPSDE PIAEAPFKFD MELDDLPKEK LKELIFEETA RFQPGYRS //